Computed tomography based radiomic signature as predictive of survival and local control after stereotactic body radiation therapy in pancreatic carcinoma

Luca Cozzi, Tiziana Comito, Antonella Fogliata, Ciro Franzese, Davide Franceschini, Cristiana Bonifacio, Angelo Tozzi, Lucia Di Brina, Elena Clerici, Stefano Tomatis, Giacomo Reggiori, Francesca Lobefalo, Antonella Stravato, Pietro Mancosu, Alessandro Zerbi, Martina Sollini, Margarita Kirienko, Arturo Chiti, Marta Scorsetti, Luca Cozzi, Tiziana Comito, Antonella Fogliata, Ciro Franzese, Davide Franceschini, Cristiana Bonifacio, Angelo Tozzi, Lucia Di Brina, Elena Clerici, Stefano Tomatis, Giacomo Reggiori, Francesca Lobefalo, Antonella Stravato, Pietro Mancosu, Alessandro Zerbi, Martina Sollini, Margarita Kirienko, Arturo Chiti, Marta Scorsetti

Abstract

Purpose: To appraise the ability of a radiomics signature to predict clinical outcome after stereotactic body radiation therapy (SBRT) for pancreas carcinoma.

Methods: A cohort of 100 patients was included in this retrospective, single institution analysis. Radiomics texture features were extracted from computed tomography (CT) images obtained for the clinical target volume. The cohort of patients was randomly divided into two separate groups for the training (60 patients) and validation (40 patients). Cox regression models were built to predict overall survival and local control. The significant predictors at univariate analysis were included in a multivariate model. The quality of the models was appraised by means of area under the curve and concordance index.

Results: A clinical-radiomic signature associated with Overall Survival (OS) was found significant in both training and validation sets (p = 0.01 and 0.05 and concordance index 0.73 and 0.75 respectively). Similarly, a signature was found for Local Control (LC) with p = 0.007 and 0.004 and concordance index 0.69 and 0.75. In the low risk group, the median OS and LC in the validation group were 14.4 and 28.6 months while in the high-risk group were 9.0 and 17.5 months respectively.

Conclusion: A CT based radiomic signature was identified which correlate with OS and LC after SBRT and allowed to identify low and high-risk groups of patients.

Conflict of interest statement

I have read the journal's policy and the authors of this manuscript have the following competing interests: L. Cozzi acts as Scientific Advisor to Varian Medical Systems and is Clinical Research Scientist at Humanitas Cancer Center. All other co-authors declare that they have no conflict interests. A. Chiti received speaker honoraria from General Electric and Sirtex Medical System; acted as scientific advisor for Blue Earth Diagnostics and Advanced Accelerator Applications; benefited from an unconditional grant from Sanofi to Humanitas University. All honoraria and grants are outside the scope of the submitted work. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1. Overall survival (OS) and local…
Fig 1. Overall survival (OS) and local control (LC) curves stratified according to the best threshold for the clinical and radiomic features found to be significant at univariate analysis.
Data are shown for the training dataset. In the figures the blue lines correspond to the stratum above the threshold.
Fig 2
Fig 2
a) and b): Overall survival (OS) and Local Control (LC) curves for the training (solid red line) and validation (blue dashed line) cohorts of patients without any stratification; c) and d): Overall survival (OS) curves for the multivariate models A and B respectively. The sub-panels represent the ROC curves built out of the models. e) and f): Local Control (LC) curves as for the above. In the survival curves, solid lines correspond to the low risk group of patients; blue lines to the validation (red for the training) set. In the ROC curves, solid line is for the training, dashed for the validation.
Fig 3. Calibration plots at 6,12 and…
Fig 3. Calibration plots at 6,12 and 18 months for the Cox models B for overall survival and local control.

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. (2013) CA Cancer J Clin 63:11–30. 10.3322/caac.21166
    1. Vincent A, Herman J, Schulick R. Pancreatic cancer. (2011) Lancet. 378:607–20. 10.1016/S0140-6736(10)62307-0
    1. Ben-Josef E, Schipper M, Francis I, Hadley S, Ten-Haken R, Lawrence T et al. (2012) A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 84:1166–1171 10.1016/j.ijrobp.2012.02.051
    1. Brunner T, Nestle U, Grosu A, Partridge M. (2015) SBRT in pancreatic cancer: What is the therapeutic windows? Radiother. Oncol. 114:109–16
    1. Chang D, Schellenberg D, Shen J, Kim J, Goodman K, Fisher G et al.: (2009) Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer 115:665–672. 10.1002/cncr.24059
    1. Schellenberg D, Kim J, Christman-Skieller C, Chun C, Columbo L. Ford J et al.: (2011) Single-Fraction Stereotactic Body Radiation Therapy and Sequential Gemcitabine for the Treatment of Locally Advanced Pancreatic Cancer. Int J Radiat Oncol Biol Phys 81:181–188. 10.1016/j.ijrobp.2010.05.006
    1. Polistina F, Costantin G, Casamassima F, Francescon P, Guglielmi R, Panizzoni G et al.: (2010) Unresectable locally advanced pancreatic cancer: A multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration. Ann Surg Oncol 17:2092–2101. 10.1245/s10434-010-1019-y
    1. Mahadevan A, Miksad R, Goldstein M, Sullivan R, Bullock A, Buchbinder E et al.: (2011) Induction Gemcitabine And Stereotactic Body Radiotherapy For Locally advanced Nonmetastatic Pancreas Cancer. Int J Radiat Oncol Biol Phys 81:615–622. 10.1016/j.ijrobp.2010.06.044
    1. Rwigema J, Parikh S, Heron D, Howell M, Zeh H, Moser A et al.: (2011) Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas. Am J Clin Oncol 34:63–69. 10.1097/COC.0b013e3181d270b4
    1. Chuong M, Springett G, Freilich J, Park C, Weber J, Mellon E et al. (2013) Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biol Phys. 86:516–522. 10.1016/j.ijrobp.2013.02.022
    1. Herman J, Chang D, Goodman K, Dholakia A, Raman S, Hacker-Prietz A et al. (2015) Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer. 121:1128–3 10.1002/cncr.29161
    1. Comito T, Cozzi L, Clerici E, Franzese C, Tozzi A, Iftode C et al. (2017) Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study. Technol. Cancer Res Treat. 16:295–301 10.1177/1533034616650778
    1. Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout R, Granton P, et al. (2012) Radiomics: Extracting more information from medical images using advanced feature analysis. Eur J Cancer 48:441–6 10.1016/j.ejca.2011.11.036
    1. Aerts H, Velazquez E, Leijenaar R, Parmar C, Grossmann P, Carvalho S, et al. (2014) Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 5:4006 10.1038/ncomms5006
    1. Yue Y, Osipov A, Fraass B, Sandler H, Zhang X, Nissen N et al. (2017) Identifying prognostic intratumor heterogeneity using pre- and post-radiotherapy 18F-FDG PET images for pancreatic cancer patients. J Gastrointest Oncol. 8:127–138 10.21037/jgo.2016.12.04
    1. Hanania A, Bantis L, Feng Z, Wang H, Tamm E, Katz M et al. (2016) Quantitative imaging to evaluate malignant potential of IPMNs. Oncotarget. 7:85776–85784 10.18632/oncotarget.11769
    1. Permuth J, Choi J, Balarunathan Y, Kim J, Chen D, Chen L et al. (2016) Combining radiomic features with a miRNA classifier may improve prediction of malignant pathology for pancreatic intraductal papillary mucinous neoplasms. Oncotarget. 7:85785–85797 10.18632/oncotarget.11768
    1. Chen X, Oshima K, Schott D, Wu H, Hall W, Song Y et al. (2017) Assessment of treatment response during chemoradiation therapy for pancreatic cancer based on quantitative radiomic analysis of daily CTs: an exploratory study. PlosOne 12:e0178961
    1. Eilaghi A, Baig S, Zhang Y, Zhang J, Karanicolas P, Gallinger S et al. (2017) CT texture features are associated with overall survival in pancreatic ductal adenocarcinoma–a quantitative analysis. BMC Med. Imag. 17:38
    1. Cozzi L, Dinapoli N, Fogliata A, Hsu W, Reggiori G, Lobefalo F et al. (2017) Radiomics based analysis to predict local control and survival in hepatocellular carcinoma patients treated with volumetric modulated arc therapy. BMC Cancer 17:829 10.1186/s12885-017-3847-7
    1. Kirienko M, Cozzi L, Antonovic L, Lozza L, Fogliata A, Voulaz E et al. (2018) Prediction of disease free survival by the PET/CT radiomic signature in non-small cell lung cancer patients undergoing surgery. Eur. J. Nucl Med Mol Imag. 45:207–271
    1. Nioche C, Orlhac F, Boughdad S, Reuzé S, Goya-Outi J, Robert C et al. LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res 2018;78:4786–4789 10.1158/0008-5472.CAN-18-0125
    1. Sollini M, Cozzi L, Antunovic L, Chiti A, Kirienko M. (2017) PET Radiomics in NSCLC: state of the art and a proposal for harmonization of methodology. Sci Rep. 7:358 10.1038/s41598-017-00426-y
    1. Sollini M, Cozzi L, Peper G, Antunovic L, Lania A, Di Tommaso L et al. (2017) [18F]FDG-PET/Ct texture analysis in thyroid incidentalomas: preliminary results. Eur. J. Hybr. Imaging. 1:3
    1. R Core Team. R: A language and environment for statistical computing R Foundation for Statistical Computing, Vienna, Austria: URL .
    1. Harrel F, Lee K, Mark D. (1996) Multivariable prognostic models: issues in developing models, adequacy and measuring and reducing errors. Stat Med. 15:361–387 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>;2-4
    1. Bogowicz M, Riesterer O, Ikenberg K, Stieb S, Moch H, Studer G et al.(2017) Computed tomography radiomics predicts HPV status and local control after definitive radiochemotherapy in head and neck squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 99:921–928 10.1016/j.ijrobp.2017.06.002
    1. Bogowicz M, Leijneaar R, Tanadini-Lang S, Riesterer O, Pruschy M, Unkelbach J et al. (2017) Post-radiochemotherapy PET radiomics in head and neck cancer- the influence of radiomics implementation on the reproducibility of local control tumor models. Radiother. Oncol. 125:385–391 10.1016/j.radonc.2017.10.023

Source: PubMed

3
S'abonner